Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE PPP2R2A prostate cancer haploinsufficiency is associated with worse prognosis and a high vulnerability to B55α/PP2A reconstitution that triggers centrosome destabilization. 31822657 2019
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE Polyphyllin I inhibits invasion and epithelial-mesenchymal transition via CIP2A/PP2A/ERK signaling in prostate cancer. 29956727 2018
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE Overall, our results provide a preclinical proof of concept for the efficacy of SMAP in AR degradation and CRPC treatment.<b>Significance:</b> A novel class of small-molecule activators of the tumor suppressor PP2A, a serine/threonine phosphatase that inhibits many oncogenic signaling pathways, is shown to deregulate the phosphoproteome and to destabilize the androgen receptor in advanced prostate cancer.<i></i>. 29358171 2018
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE URI Regulates KAP1 Phosphorylation and Transcriptional Repression via PP2A Phosphatase in Prostate Cancer Cells. 27780869 2016
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression disease BEFREE Moreover, recent findings highlight that functional inactivation of PP2A could represent a key event in the acquisition of castration-resistant phenotype and a novel molecular target with high impact at both clinical and therapeutic levels in prostate cancer. 26234767 2015
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE Furthermore, loss of SPRY2 expression correlates strongly with loss of PTEN and/or PP2A subunits in human prostate cancer. 23434594 2013
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE We conclude that loss of expression of scaffold and regulatory subunits of PP2A is responsible for its altered function during PCa pathogenesis. 23598299 2013
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression disease BEFREE Our data show that the PPP2CA expression and PP2A activity is downregulated in androgen-independent (C4-2) prostate cancer cells as compared with androgen-dependent (LNCaP) cells. 21393425 2011
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE Further investigation of one of the genes, PPP2CA, which encodes the catalytic subunit of a serine phosphatase PP2A, a potent tumor suppressor, revealed that its expression was decreased in prostate cancer compared to adjacent normal/benign tissue. 17977648 2008
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 GeneticVariation disease BEFREE The PP2A-AR interaction was used to show that an AR mutant in prostate cancer cells (T877A) is activated by multiple ligands without acquiring the same conformation as that induced by androgen. 17325038 2007
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression disease BEFREE The N terminus of PP6 or PP2A was fused to GFP and the proteins transiently expressed in prostate cancer PC-3 cells. 17568194 2007